Abstract:Pick’s disease (PiD), a behavioral variant of frontotemporal dementia, is one of the common neurodegenerative dementia that is characterized by tau lesions. Despite the distinct tau aggregation observed in Pick’s disease compared with the tauopathy of Alzheimer’s disease (AD), the similarity in cognitive and behavioral impairments during the progression of the disease make their diagnosis challenging. What determines the differences and similarities between PiD and AD progression, especially at the epigenetic level, are largely unknown. We believe that recent advancement in single‐cell epigenomic profiling methods, Assay for Transposase‐Accessible Chromatin (ATAC) combined with high throughput sequencing, will enable us to map the chromatin‐regulatory landscapes of disease brains at a single‐cell resolution and enable us to understand underlying molecular changes in these diseases. In the present study, we have isolated single nuclei from the frontal cortex region and performed single‐nucleus ATAC sequencing (snATAC‐seq) of 198,722 nuclei to generate cell‐type specific chromatin accessibility profiles of postmortem brains of PiD and AD patients and to uncover their cellular heterogeneity and similarity. We used cellranger to process the paired‐end FastQ reads of each sample to obtain its chromatin accessibility count matrix. Next, we utilized ArchR and Signac pipelines to generate 501‐bp fixed‐width peak regions and performed downstream differential accessible regions analysis. Quality control was also performed to remove the contribution of low‐quality nuclei. We constructed chromatin accessibility profiles from 19,690 nuclei from PiD patients, 59,148 nuclei from AD patients, and 119,884 nuclei from healthy controls. We applied UMAP dimensionality reduction and clustered nuclei through open chromatin region to the batch‐corrected epigenomic datasets. We identified seven distinct cell types, including astrocyte, excitatory neurons, inhibitory neurons, microglia, oligodendrocytes, OPC, and pericyte/endothelial cells, and we applied pseudotime trajectory analysis to characterize disease‐associated cell state in both AD and PiD at the epigenomics level. Our data identified the cell‐type‐specific open chromatin accessible regions in AD and PiD brains. Although the causative molecular mechanisms of AD and PiD remain unknown, our work helps to identify shared epigenomic changes in AD and PiD, especially in regards to cell‐type‐specific genomic loci with disease risk.

Single-nucleus multi-omics identifies shared and distinct pathways in Pick’s and Alzheimer’s disease

Single-nucleus multi-omics identifies shared and distinct pathways in Pick's and Alzheimer's disease

Single‐nucleus open chromatin accessibility landscape of Pick’s and Alzheimer’s disease

Single-nucleus chromatin accessibility and transcriptomic characterization of Alzheimer’s disease

Cross-disorder and disease-specific pathways in dementia revealed by single-cell genomics

Integrated Identification of Key Genes and Pathways in Alzheimer’s Disease Via Comprehensive Bioinformatical Analyses

Single-nucleus and spatial transcriptomic profiling of human temporal cortex and white matter reveals novel associations with AD pathology

An integrated multi-omics approach identifies epigenetic alterations associated with Alzheimer’s disease

Identifying Alzheimer's disease-related pathways based on whole-genome sequencing data

An integrative multi-omics approach reveals new central nervous system pathway alterations in Alzheimer's disease

An integrative, hypothesis‐free, multi‐omics approach uncovers biological pathway alterations in Alzheimer’s disease

Identification of novel drug targets for Alzheimer’s disease by integrating genetics and proteomes from brain and blood

Integrated spatial and single‐cell transcriptomic analysis of genetic and sporadic forms of Alzheimer’s disease

Personalized Single-cell Transcriptomics Reveals Molecular Diversity in Alzheimer's Disease

Single-cell transcriptomic analysis of Alzheimer’s disease

Comparative mapping of single-cell transcriptomic landscapes in neurodegenerative diseases

Single-cell atlas of transcriptomic vulnerability across multiple neurodegenerative and neuropsychiatric diseases

Identification of Novel Drug Targets for Alzheimer's Disease by Integrating Genetics and Proteomes from Brain and Blood.

Genetic and multi-omic risk assessment of Alzheimer's disease implicates core associated biological domains

Brain high-throughput multi-omics data reveal molecular heterogeneity in Alzheimer's disease

Deep multilayer brain proteomics identifies molecular networks and Netrin‐1 accumulation in Alzheimer’s disease progression: Genetics/omics and systems biology